NEWS-PrimeLink BioTherapeutics_ADC Biotechnology

Home page

PrimeLink Bio’s PLB-002 Wins NMPA IND Approval, Marking China-US Dual Filing

PrimeLink Bio’s PLB-002 Wins NMPA IND Approval, Marking China-US Dual Filing

20 Nov,2025

Flexible, Modular Tech Platform Overcomes Conventional ADC Toxicity and Resistance Limits

Flexible, Modular Tech Platform Overcomes Conventional ADC Toxicity and Resistance Limits

02 Jan,2025

FDA Greenlights PrimeLink Bio’s Clinical Trial of PLB-002

FDA Greenlights PrimeLink Bio’s Clinical Trial of PLB-002

09 Oct,2025

Dual-Payload ADCs: A New Chapter in Cancer Therapy

Dual-Payload ADCs: A New Chapter in Cancer Therapy

10 Mar,2025

PLB-002, PrimeLink Bio’s Anti-Claudin 6 ADC, Receives IND Acceptance from NMPA and FDA

PLB-002, PrimeLink Bio’s Anti-Claudin 6 ADC, Receives IND Acceptance from NMPA and FDA

08 Sep,2025

Breaking: PrimeLink Bio Named 2025 Shenzhen Seed Unicorn

Breaking: PrimeLink Bio Named 2025 Shenzhen Seed Unicorn

31 Jul,2025

< 1 2 >

免费热线

Tel:

0086 512-62652000

免费热线

E-mail:

hr@primelinkbio.com

Add:

Building 4, Suhua Science Park , No.208 Tongyuan Road, Suzhou Industrial Park

Follow Us

©2022 PrimeLink BioTherapeutics Powered by：CEglobal